Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TINN2: Azithromycin for the Prevention of Chronic Lung Disease of Prematurity
NCT02282176Phase 3Withdrawn
- Sponsor
- Inserm
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of azithromycin in bronchopulmonary dysplasia (BPD), sponsored by Inserm. Planned start Jan 2015; status: withdrawn.
02
Drugs
azithromycin
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT02282176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282176.